{"organizations": [], "uuid": "2a9a61833c0cf88e4024008bdde0f774aaa7af70", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180503.html", "section_title": "Archive News &amp; Video for Thursday, 03 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-alnylam-pharmaceuticals-reports-q1/brief-alnylam-pharmaceuticals-reports-q1-loss-per-share-of-1-41-idUSASC09ZMI", "country": "US", "domain_rank": 408, "title": "Alnylam Pharmaceuticals Reports Q1 Loss Per Share Of $1.41", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-04T04:27:00.000+03:00", "replies_count": 0, "uuid": "2a9a61833c0cf88e4024008bdde0f774aaa7af70"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-alnylam-pharmaceuticals-reports-q1/brief-alnylam-pharmaceuticals-reports-q1-loss-per-share-of-1-41-idUSASC09ZMI", "ord_in_thread": 0, "title": "Alnylam Pharmaceuticals Reports Q1 Loss Per Share Of $1.41", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "alnylam pharmaceuticals", "sentiment": "negative"}, {"name": "alnylam pharmaceuticals inc", "sentiment": "negative"}, {"name": "thomson reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 3 (Reuters) - Alnylam Pharmaceuticals Inc:\n* ALNYLAM PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PERIOD ACTIVITY\n* Q1 NON-GAAP LOSS PER SHARE $1.22\n* Q1 REVENUE VIEW $33.6 MILLION — THOMSON REUTERS I/B/E/S * Q1 EARNINGS PER SHARE VIEW $-1.47 — THOMSON REUTERS I/B/E/S\n* ALNYLAM PHARMACEUTICALS - REMAINS ON TRACK TO END 2018 WITH ABOUT $1.0 BILLION OF CASH, CASH EQUIVALENTS, AMONG OTHERS\n* NOW EXPECTS ITS 2018 ANNUAL NON-GAAP RESEARCH AND DEVELOPMENT EXPENSES TO BE IN RANGE OF $420 MILLION TO $460 MILLION Source text for Eikon:\nOur ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-04T04:27:00.000+03:00", "crawled": "2018-05-04T16:37:06.005+03:00", "highlightTitle": ""}